Effects of Drugs of Abuse on Cytokine Responses

  • Stephen B. Pruett
Part of the Methods in Pharmacology and Toxicology book series (MIPT)


In the United States, the association between drugs of abuse and increased risk of infection has been suspected since colonial times. More recent studies have confirmed this relationship for most commonly abused drugs. Studies in animal models and in human subjects indicate that this increased susceptibility to infection is associated with decreased effectiveness of important innate and acquired immune defense mechanisms. All of the major drugs of abuse have been reported to affect cytokine and chemokine responses, which are critical in resistance to most infections. In general, proinflammatory, proimmune cytokine responses are decreased and anti-inflammatory, immunosuppressive cytokine responses are increased. The mechanisms by which this occurs have not been fully delineated, but receptor mediated effects, which probably act by interfering with immune stimulus-mediated signaling and indirect effects mediated by stress hormones, clearly are involved in the action of most drugs of abuse.

Key Words

Cytokine chemokine ethanol cannabinoid marijuana nicotine tobacco cocaine opioid 


  1. 1.
    Leonard WJ. Type I cytokines and interferons and their receptors. In: Paul WE, ed. Fundamental Immunology. Philadelphia: Lippincott Williams & Wilkins; 2003:701–747.Google Scholar
  2. 2.
    Murphy PM. Chemokines. In: Paul WE, ed. Fundamental Immunology. Philadelphia: Lippincott Williams & Wilkins; 2003:801–840.Google Scholar
  3. 3.
    Andrews P. Cocaethylene toxicity. J Addict Dis 1997; 16:75–84.PubMedGoogle Scholar
  4. 4.
    House RV, Thomas PT, Bhargava HN. In vitro exposure to peptidic delta opioid receptor antagonists results in limited immunosuppression. Neuropeptides 1997;31:89–93.PubMedGoogle Scholar
  5. 5.
    Wetzel MA, Steele AD, Eisenstein TK, Adler MW, Henderson EE, Rogers TJ. Mu-opioid induction of monocyte chemoattractant protein-1, RANTES, and IFN-gamma-inducible protein-10 expression in human peripheral blood mononuclear cells. J Immunol 2000; 165:6519–6524.PubMedGoogle Scholar
  6. 6.
    Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421:384–388.PubMedGoogle Scholar
  7. 7.
    Pruett SB, Obiri N, Kiel JL. Involvement and relative importance of at least two distinct mechanisms in the effects of 2-mercaptoethanol on murine lymphocytes in culture. J Cell Physiol 1989; 141:40–45.PubMedGoogle Scholar
  8. 8.
    Bhat RS, Bhaskaran M, Mongia A, Hitosugi N, Singhal PC. Morphine-induced macrophage apoptosis: oxidative stress and strategies for modulation. J Leukoc Biol 2004;75:1131–1138.PubMedGoogle Scholar
  9. 9.
    Patel K, Bhaskaran M, Dani D, Reddy K, Singhal PC. Role of heme oxygenase-1 in morphine-modulated apoptosis and migration of macrophages. J Infect Dis 2003; 187:47–54.PubMedGoogle Scholar
  10. 10.
    Sci Y, Yoshimoto K, Mclntyre T, Skolnick P, Arora PK. Morphine-induced thymic hypoplasia is glucocorticoid-dependent. J Immunol 1991; 146:194–198.Google Scholar
  11. 11.
    House RV, Thomas PT, Bhargava H. In vitro evaluation of fentanyl and meperidine for immunomodulatory activity. Immunol Lett 1995;46:117–124.PubMedGoogle Scholar
  12. 12.
    Thomas PT, Bhargava HN, House RV. Immunomodulatory effects of in vitro exposure to morphine and its metabolites. Pharmacology 1995;50:51–62.PubMedGoogle Scholar
  13. 13.
    Suzuki S, Chuang AJ, Chuang LF, Doi RH, Chuang RY. Morphine promotes simian acquired immunodeficiency syndrome virus replication in monkey peripheral mononuclear cells: induction of CC chemokine receptor 5 expression for virus entry. J Infect Dis 2002;185:1826–1829.PubMedGoogle Scholar
  14. 14.
    Homan JW, Steele AD, Martinand-Mari C, et al. Inhibition of morphinepotentiated HIV-1 replication in peripheral blood mononuclear cells with the nuclease-resistant 2-5A agonist analog, 2-5A(N6B). J Acquir Immune Defic Syndr 2002;30:9–20.PubMedGoogle Scholar
  15. 15.
    Mou L, Lankford-Turner P, Leander MV, Bissonnette RP, Donahoe RM, Royal W. RXR-induced TNF-alpha suppression is reversed by morphine in activated U937 cells. J Neuroimmunol 2004; 147:99–105.PubMedGoogle Scholar
  16. 16.
    Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol 1998;83:77–87.PubMedGoogle Scholar
  17. 17.
    Nyland SB, Specter S, Ugen KE. Morphine effects on HTLV-I infection in the presence or absence of concurrent HIV-1 infection. DNA Cell Biol 1999;18: 285–291.PubMedGoogle Scholar
  18. 18.
    Krol A, Flynn C, Vlahov D, Miedema F, Coutinho RA, van Ameijden EJ. New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users. Drug Alcohol Depend 1999;54:145–154.PubMedGoogle Scholar
  19. 19.
    McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001;62:111–123.PubMedGoogle Scholar
  20. 20.
    Vallejo R, De Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004;l 1:354–365.Google Scholar
  21. 21.
    Bussiere JL, Adler MW, Rogers TJ, Eisenstein TK. Cytokine reversal of morphine-induced suppression of the antibody response. J Pharmacol Exp Ther 1993;264:591–597.PubMedGoogle Scholar
  22. 22.
    Wang J, Charboneau R, Balasubramanian S, Barke RA, Loh HH, Roy S. The immunosuppressive effects of chronic morphine treatment are partially dependent on corticosterone and mediated by the mu-opioid receptor. J Leukoc Biol 2002;71:782–790.PubMedGoogle Scholar
  23. 23.
    Eisenstein TK, Bussiere JL, Rogers TJ, Adler MW. Immunosuppressive effects of morphine on immune responses in mice. Adv Exp Med Biol 1993;335:41–52.PubMedGoogle Scholar
  24. 24.
    Ho BT, Lu JG, Huo YY, et al. The opioid mechanism of interferon-alpha action. Anticancer Drugs 1994;5:90–94.PubMedGoogle Scholar
  25. 25.
    Saphier D. Neuroendocrine effects of interferon-alpha in the rat. Adv Exp Med Biol 1995;373:209–218.PubMedGoogle Scholar
  26. 26.
    Sacerdote P. Effects of in vitro and in vivo opioids on the production of IL-12 and IL-10 by murine macrophages. Ann NY Acad Sci 2003;992:129–140.PubMedGoogle Scholar
  27. 27.
    Peng X, Mosser DM, Adler MW, Rogers TJ, Meissler JJ Jr., Eisenstein TK. Morphine enhances interleukin-12 and the production of other pro-inflammatory cytokines in mouse peritoneal macrophages. J Leukoc Biol 2000;68:723–728.PubMedGoogle Scholar
  28. 28.
    Nelson CJ, Lysle DT. Morphine modulation of the contact hypersensitivity response: characterization of immunological changes. Clin Immunol 2001;98:370–377.PubMedGoogle Scholar
  29. 29.
    Limiroli E, Gaspani L, Panerai AE, Sacerdote P. Differential morphine tolerance development in the modulation of macrophage cytokine production in mice. J Leukoc Biol 2002;72:43–48.PubMedGoogle Scholar
  30. 30.
    Pacifici R, diCarlo S, Bacosi A, Pichini S, Zuccaro P. Pharmacokinetics and cytokine production in heroin and morphine-treated mice. Int J Immunopharmacol 2000;22:603–614.PubMedGoogle Scholar
  31. 31.
    Walker JS. Anti-inflammatory effects of opioids. Adv Exp Med Biol 2003;521:148–160.PubMedGoogle Scholar
  32. 32.
    Philippe D, Dubuquoy L, Groux H, et al. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest 2003;l 11:1329–1338.Google Scholar
  33. 33.
    Wang J, Barke RA, Charboneau R, Roy S. Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol 2005; 174:426–434.PubMedGoogle Scholar
  34. 34.
    LeVier DG, McCay JA, Stern ML, et al. Immunotoxicological profile of morphine sulfate in B6C3F1 female mice. Fundam Appl Toxicol 1994;22: 525–542.PubMedGoogle Scholar
  35. 35.
    Conlan JW, North RJ. Listeria monocytogenes, but not Salmonella typhimurium, elicits a CD 18-independent mechanism of neutrophil extravasation into the murine peritoneal cavity. Infect Immun 1994;62:2702–2706.PubMedGoogle Scholar
  36. 36.
    Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2001;2:343–372.PubMedGoogle Scholar
  37. 37.
    Louria DB, Hensle T, Rose J. The major medical complications of heroin addiction. Ann Intern Med 1967;67:1–22.PubMedGoogle Scholar
  38. 38.
    Kay DC, Pickworth WB, Neider GL. Morphine-like insomnia from heroin in nondependent human addicts. Br J Clin Pharmacol 1981; 11:159–169.PubMedGoogle Scholar
  39. 39.
    el-Nakah A, Frank O, Louria DB, Quinones MA, Baker H. A vitamin profile of heroin addiction. Am J Public Health 1979;69:1058–1060.PubMedGoogle Scholar
  40. 40.
    Akural El, Salomaki TE, Bloigu AH, et al. The effects of pre-emptive epidural sufentanil on human immune function. Acta Anaesthesiol Scand 2004;48: 750–755.PubMedGoogle Scholar
  41. 41.
    Negishi C, Lenhardt R, Ozaki M, et al. Opioids inhibit febrile responses in humans, whereas epidural analgesia does not: an explanation for hyperthermia during epidural analgesia. Anesthesiology 2001;94:218–222.PubMedGoogle Scholar
  42. 42.
    Yeager MP, Colacchio TA, Yu CT, et al. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 1995;83:500–508.PubMedGoogle Scholar
  43. 43.
    Song LC, Song C, Zeng J, Xiong ML, Lou N. Reduction in monocyte chemoattractant protein-1 mRNA expression in peripheral blood mononuclear cells of diamorphine addicts. Acta Pharmacol Sin 2002;23:336–338.PubMedGoogle Scholar
  44. 44.
    Horn SD, Wright HL, Couperus JJ, et al. Association between patient-controlled analgesia pump use and postoperative surgical site infection in intestinal surgery patients. Surg Infect (Larchmt) 2002;3(2): 109–118.Google Scholar
  45. 45.
    Brand JM, Frohn C, Luhm J, Kirchner H, Schmucker P. Early alterations in the number of circulating lymphocyte subpopulations and enhanced proinflammatory immune response during opioid-based general anesthesia. Shock 2003;20:213–217.PubMedGoogle Scholar
  46. 46.
    Zajicova A, Wilczek H, Holan V. The alterations of immunological reactivity in heroin addicts and their normalization in patients maintained on methadone. Folia Biol (Praha) 2004;50:24–28.Google Scholar
  47. 47.
    Brix-Christensen V, Tonnesen E, Sorensen IJ, Bilfinger TV, Sanchez RG, Stefano GB. Effects of anaesthesia based on high versus low doses of opioids on the cytokine and acute-phase protein responses in patients undergoing cardiac surgery. Acta Anaesthesiol Scand 1998;42:63–70.PubMedGoogle Scholar
  48. 48.
    Heathcote J, Taylor KB. Immunity and nutrition in heroin addicts. Drug Alcohol Depend 1981;8:245–255.PubMedGoogle Scholar
  49. 49.
    Rahim RT, Meissler JJ, Zhang L, Adler MW, Rogers TJ, Eisenstein TK. Withdrawal from morphine in mice suppresses splenic macrophage function, cytokine production, and costimulatory molecules. J Neuroimmunol 2003; 144:16–27.PubMedGoogle Scholar
  50. 50.
    Bussiere JL, Adler MW, Rogers TJ, Eisenstein TK. Differential effects of morphine and naltrexone on the antibody response in various mouse strains. Immunopharmacol Immunotoxicol 1992;14:657–673.PubMedGoogle Scholar
  51. 51.
    Freier DO, Fuchs BA. A mechanism of action for morphine-induced immunosuppression: corticosterone mediates morphine-induced suppression of natural killer cell activity. J Pharmacol Exp Ther 1994;270:1127–1133.PubMedGoogle Scholar
  52. 52.
    Fuchs BA, Pruett SB. Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: involvement of both opiate and glucocorticoid receptors. J Pharmacol Exp Ther 1993;266:417–423.PubMedGoogle Scholar
  53. 53.
    Bussiere J, Adler M, Rogers T, Eisenstein T. Interleukin-6 reverses morphine-induced suppression of the antibody response. NIDA Research Monograph Series 1992; 119.Google Scholar
  54. 54.
    Pruett SB, Han YC, Fuchs BA. Morphine suppresses primary humoral immune responses by a predominantly indirect mechanism. J Pharmacol Exp Ther 1992;262:923–928.PubMedGoogle Scholar
  55. 55.
    Taub DD, Eisenstein TK, Geller EB, Adler MW, Rogers TJ. Immumomodulatory activity of μ-and k-selective opioid agonists. Proc Natl Acad Sci USA 1991;88:360–364.PubMedGoogle Scholar
  56. 56.
    Eisenstein TK, Meissler JJ, Jr., Rogers TJ, Geller EB, Adler MW. Mouse strain differences in immunosuppression by opioids in vitro. J Pharmacol Exp Ther 1995;275:1484–1489.PubMedGoogle Scholar
  57. 57.
    Hedin KE, Bell MP, Huntoon CJ, Karnitz LM, McKean DJ. Gi proteins use a novel beta gamma-and Ras-independent pathway to activate extracellular signal-regulated kinase and mobilize AP-1 transcription factors in Jurkat T lymphocytes. J Biol Chem 1999;274:19,992–20,001.PubMedGoogle Scholar
  58. 58.
    Shahabi NA, Daaka Y, McAllen K, Sharp BM. Delta opioid receptors expressed by stably transfected jurkat cells signal through the map kinase pathway in a rasindependent manner. J Neuroimmunol 1999;94:48–57.PubMedGoogle Scholar
  59. 59.
    Heagy W, Shipp MA, Finberg RW. Opioid receptor agonists and Ca2+ modulation in human B cell lines. J Immunol 1992; 149:4074–4081.PubMedGoogle Scholar
  60. 60.
    O’Brien CP. Drug addiction and drug abuse. In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2001, pp. 621–642.Google Scholar
  61. 61.
    Roy S, Barke RA, Loh HH. Mu-opioid receptor knockout mice: role of mu-opioid receptor in morphine mediated immune functions. Brain Res Mol Brain Res 1998;61:190–194.PubMedGoogle Scholar
  62. 62.
    Szabo I, Chen XH, Xin L, et al. Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc Natl Acad Sci USA 2002;99:10,276–10,281.PubMedGoogle Scholar
  63. 63.
    Zhang N, Rogers TJ, Caterina M, Oppenheim JJ. Proinflammatory chemokines, such as C-C chemokine ligand 3, desensitize mu-opioid receptors on dorsal root ganglia neurons. J Immunol 2004; 173:594–599.PubMedGoogle Scholar
  64. 64.
    Zhang N, Hodge D, Rogers TJ, Oppenheim JJ. Ca2+-independent protein kinase Cs mediate heterologous desensitization of leukocyte chemokine receptors by opioid receptors. J Biol Chem 2003;278:12,729–12,736.PubMedGoogle Scholar
  65. 65.
    Rogers TJ, Steele AD, Howard OM, Oppenheim JJ. Bidirectional heterologous desensitization of opioid and chemokine receptors. Ann NY Acad Sci 2000; 917:19–28.PubMedGoogle Scholar
  66. 66.
    Szabo I, Wetzel MA, Zhang N, et al. Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heter-ologous desensitization. J Leukoc Biol 2003;74:1074–1082.PubMedGoogle Scholar
  67. 67.
    Jan TR, Rao GK, Kaminski NE. Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. Mol Pharmacol 2002;61:446–454.PubMedGoogle Scholar
  68. 68.
    Smith SR, Denhardt G, Terminelli C. The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. Eur J Pharmacol 2001;432:107–119.PubMedGoogle Scholar
  69. 69.
    Juttler E, Potrovita I, Tarabin V, et al. The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappaB). Neuropharmacology 2004;47: 580–592.PubMedGoogle Scholar
  70. 70.
    Lavon I, Sheinin T, Meilin S, et al. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. Mol Pharmacol 2003;64:1334–1341.PubMedGoogle Scholar
  71. 71.
    Herring AC, Faubert Kaplan BL, Kaminski NE. Modulation of CREB and NF-kappaB signal transduction by cannabinol in activated thymocytes. Cell Signal 2001;13:241–250.PubMedGoogle Scholar
  72. 72.
    Faubert Kaplan BL, Kaminski NE. Cannabinoids inhibit the activation of ERK MAPK in PMA/Io-stimulated mouse splenocytes. Int Immunopharmacol 2003;3:1503–1510.PubMedGoogle Scholar
  73. 73.
    Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 2003;41:161–168.PubMedGoogle Scholar
  74. 74.
    Coffey RG, Yamamoto Y, Snella E, Pross S. Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochem Pharmacol 1996;52:743–751.PubMedGoogle Scholar
  75. 75.
    Croci T, Landi M, Galzin AM, Marini P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 2003;140:115–122.PubMedGoogle Scholar
  76. 76.
    Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004; 113:1202–1209.PubMedGoogle Scholar
  77. 77.
    Jan TR, Kaminski NE. Role of mitogen-activated protein kinases in the differential regulation of interleukin-2 by cannabinol. J Leukoc Biol 2001;69:841–849.PubMedGoogle Scholar
  78. 78.
    Klein TW, Newton C, Larsen K, et al. Cannabinoid receptors and T helper cells. J Neuroimmunol 2004; 147:91–94.PubMedGoogle Scholar
  79. 79.
    Smith SR, Terminelli C, Denhardt G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and antiinflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 2000;293:136–150.PubMedGoogle Scholar
  80. 80.
    Chang YH, Lee ST, Lin WW. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem 2001;81:715–723.PubMedGoogle Scholar
  81. 81.
    Pacifici R, Zuccaro P, Pichini S, et al. Modulation of the immune system in cannabis users. JAMA 2003;289:1929–1931.PubMedGoogle Scholar
  82. 82.
    Roth MD, Baldwin GC, Tashkin DP. Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 2002;121: 229–239.PubMedGoogle Scholar
  83. 83.
    Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 2002;42(ll Suppl):71S–81S.PubMedGoogle Scholar
  84. 84.
    Bredt BM, Higuera-Alhino D, Shade SB, Hebert SJ, McCune JM, Abrams DI. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol 2002;42(11 Suppl):82S–89S.PubMedGoogle Scholar
  85. 85.
    Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 2003; 139:258–266.PubMedGoogle Scholar
  86. 86.
    Killestein J, Hoogervorst EL, Reif M, et al. Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. J Neuroimmunol 2003; 137:140–143.PubMedGoogle Scholar
  87. 87.
    Johnson KM, Dewey WL, Ritter KS, Beckner JS. Cannabinoid effects on plasma corticosterone and uptake of 3H-corticosterone by mouse brain. Eur J Pharmacol 1978;47:303–310.PubMedGoogle Scholar
  88. 88.
    Herring AC, Koh WS, Kaminski NE. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kB elements by cannabinol, a minimally CNS-active cannabinoid. Biochem Pharmacol 1998;55:1013–1023.PubMedGoogle Scholar
  89. 89.
    Herring AC, Kaminski NE. Cannabinol-mediated inhibition of nuclear factor-kB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. J Pharmacol Exp Ther 1999;291:1156–1163.PubMedGoogle Scholar
  90. 90.
    Faubert BL, Kaminski NE. AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J Leukoc Biol 2000;67:259–266.PubMedGoogle Scholar
  91. 91.
    Davis MI, Ronesi J, Lovinger DM. A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. J Biol Chem 2003;278:48,973–48,780.PubMedGoogle Scholar
  92. 92.
    Alberich Jorda M, Rayman N, Tas M, et al. The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a liganddependent manner. Blood 2004; 104:526–534.Google Scholar
  93. 93.
    Galve-Roperh I, Rueda D, Gomez del Pulgar T, Velasco G, Guzman M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol 2002;62:1385–1392.PubMedGoogle Scholar
  94. 94.
    Rao GK, Zhang W, Kaminski NE. Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells. J Leukoc Biol 2004;75:884–892.PubMedGoogle Scholar
  95. 95.
    Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997;52:483–486.PubMedGoogle Scholar
  96. 96.
    Hoffman BB, Taylor P. Neurotransmission. In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2001, p. 144.Google Scholar
  97. 97.
    Matsumoto RR, McCracken KA, Pouw B, Zhang Y, Bowen WD. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 2002;42: 1043–1055.PubMedGoogle Scholar
  98. 98.
    Gardner B, Zhu LX, Roth MD, Tashkin DP, Dubinett SM, Sharma S. Cocaine modulates cytokine and enhances tumor growth through sigma receptors. J Neuroimmunol 2004; 147:95–98.PubMedGoogle Scholar
  99. 99.
    Stanulis ED, Matulka RA, Jordan SD, Rosecrans JA, Holsapple MP. Role of corticosterone in the enhancement of the antibody response after acute cocaine administration. J Pharmacol Exp Ther 1997;280:284–291.PubMedGoogle Scholar
  100. 100.
    Stanulis ED, Jordan SD, Rosecrans JA, Holsapple MP. Disruption of Th1/ Th2 cytokine balance by cocaine is mediated by corticosterone. Immunopharmacology 1997;37:25–33.PubMedGoogle Scholar
  101. 101.
    Broadbear JH, Winger G, Woods JH. S elf-administration of fentanyl, cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys. Psychopharmacology (Berl) 2004; 176:398–406.Google Scholar
  102. 102.
    Heesch CM, Negus BH, Keffer JH, Snyder RW 2nd, Risser RC, Eichhorn EJ. Effects of cocaine on cortisol secretion in humans. Am J Med Sci 1995;310: 61–64.PubMedGoogle Scholar
  103. 103.
    Baumann MH, Gendron TM, Becketts KM, Henningfield JE, Gorelick DA, Rothman RB. Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. Biol Psychiatry 1995;38:751–755.PubMedGoogle Scholar
  104. 104.
    Mao JT, Huang M, Wang J, Sharma S, Tashkin DP, Dubinett SM. Cocaine down-regulates IL-2-induced peripheral blood lymphocyte IL-8 and IFN-gamma production. Cell Immunol 1996;172:217–223.PubMedGoogle Scholar
  105. 105.
    Wang Y, Huang DS, Watson RR. In vivo and in vitro cocaine modulation on production of cytokines in C57BL/6 mice. Life Sci 1994;54:401–411.PubMedGoogle Scholar
  106. 106.
    Gan X, Zhang L, Newton T, et al. Cocaine infusion increases interferon-gamma and decreases interleukin-10 in cocaine-dependent subjects. Clin Immunol Immunopathol 1998;89:181–190.PubMedGoogle Scholar
  107. 107.
    Chao CC, Molitor TW, Gekker G, Murtaugh MP, Peterson PK. Cocaine-mediated suppression of Superoxide production by human peripheral blood mononuclear cells. J Pharmacol Exp Ther 1991;256:255–258.PubMedGoogle Scholar
  108. 108.
    Di Francesco P, Marini S, Pica F, Favalli C, Tubaro E, Garaci E. In vivo cocaine administration influences lymphokine production and humoral immune response. Immunol Res 1992; 11:74–79.Google Scholar
  109. 109.
    Casalinuovo IA, Gaziano R, Di Francesco P. Cytokine pattern secretion by murine spleen cells after inactivated Candida albicans immunization. Effect of cocaine and morphine treatment. Immunopharmacol Immunotoxicol 2000;22:35–48.PubMedGoogle Scholar
  110. 110.
    Kubera M, Filip M, Basta-Kaim A, et al. The effect of cocaine sensitization on mouse immunoreactivity. Eur J Pharmacol 2004;483:309–315.PubMedGoogle Scholar
  111. 111.
    Pacifici R, Fiaschi AI, Micheli L, et al. Immunosuppression and oxidative stress induced by acute and chronic exposure to cocaine in rat. Int Immunopharmacol 2003;3:581–592.PubMedGoogle Scholar
  112. 112.
    Zhu LX, Sharma S, Gardner B, et al. IL-10 mediates sigma 1 receptor-dependent suppression of antitumor immunity. J Immunol 2003;170:3585–3591.PubMedGoogle Scholar
  113. 113.
    Pruett SB. Quantitative aspects of stress-induced immunomodulation. Int Immunopharmacol 2001;1:507–520.PubMedGoogle Scholar
  114. 114.
    Dhabhar FS. Stress-induced enhancement of cell-mediated immunity. Ann NY Acad Sci 1998;840:359–372.PubMedGoogle Scholar
  115. 115.
    Tashkin DP. Evidence implicating cocaine as a possible risk factor for HIV infection. J Neuroimmunol 2004; 147:26–27.PubMedGoogle Scholar
  116. 116.
    Nair MP, Schwartz SA, Mahajan SD, et al. Drug abuse and neuropathogenesis of HIV infection: role of DC-SIGN and IDO. J Neuroimmunol 2004;157:56–60.PubMedGoogle Scholar
  117. 117.
    Shay AH, Choi R, Whittaker K, et al. Impairment of antimicrobial activity and nitric oxide production in alveolar macrophages from smokers of marijuana and cocaine. J Infect Dis 2003; 187:700–704.PubMedGoogle Scholar
  118. 118.
    Halpern JH, Sholar MB, Glowacki J, Mello NK, Mendelson JH, Siegel AJ. Diminished interleukin-6 response to proinflammatory challenge in men and women after intravenous cocaine administration. J Clin Endocrinol Metab 2003;88:1188–1193.PubMedGoogle Scholar
  119. 119.
    Baldwin GC, Buckley DM, Roth MD, Kleerup EC, Tashkin DP. Acute activation of circulating polymorphonuclear neutrophils following in vivo administration of cocaine. A potential etiology for pulmonary injury. Chest 1997; 111: 698–705.PubMedGoogle Scholar
  120. 120.
    Dhabhar FS, McEwen BS. Stress-induced enhancement of antigen-specific cell-mediated immunity. J Immunol 1996;156:2608–2615.PubMedGoogle Scholar
  121. 121.
    Contoreggi C, Herning RI, Koeppl B, et al. Treatment-seeking inpatient cocaine abusers show hypothalamic dysregulation of both basal prolactin and cortisol secretion. Neuroendocrinology 2003;78:154–162.PubMedGoogle Scholar
  122. 122.
    Grattendick K, Jansen DB, Lefkowitz DL, Lefkowitz SS. Cocaine causes increased type I interferon secretion by both L929 cells and murine macrophages. Clin Diagn Lab Immunol 2000;7:245–250.PubMedGoogle Scholar
  123. 123.
    Lee YW, Hennig B, Fiala M, Kim KS, Toborek M. Cocaine activates redoxregulated transcription factors and induces TNF-alpha expression in human brain endothelial cells. Brain Res 2001;920:125–133.PubMedGoogle Scholar
  124. 124.
    Chiappelli F, Kung MA, Villanueva P, Lee P, Frost P, Prieto N. Immunotoxicity of cocaethylene. Immunopharmacol Immunotoxicol 1995; 17:399–417.PubMedGoogle Scholar
  125. 125.
    Rush B. An enquiry into the effects of ardent spirits upon the human body and mind with an account of the means of preventing and of the remedies for curing them (reprinted). Q J Stud Alcohol 1943;4:325–341.Google Scholar
  126. 126.
    Cook RT. Alcohol abuse, alcoholism, and damage to the immune system-a review. Alcohol Clin Exp Res 1998;22:1927–1942.PubMedGoogle Scholar
  127. 127.
    Poikolainen K. Estimated lethal ethanol concentrations in relation to age, aspiration, and drugs. Alcohol Clin Exp Res 1984;8:223–225.PubMedGoogle Scholar
  128. 128.
    Urso T, Gavaler JS, Van Thiel DH. Blood ethanol levels in sober alcohol users seen in an emergency room. Life Sci 1981;28:1053–1056.PubMedGoogle Scholar
  129. 129.
    Mandrekar P, Catalano D, Girouard L, Szabo G. Human monocyte IL-10production is increased by acute ethanol treatment. Cytokine 1996;8:567–577.PubMedGoogle Scholar
  130. 130.
    Szabo G, Mandrekar P, Catalano D. Inhibition of superantigen-induced T cell proliferation and monocyte IL-1 beta, TNF-alpha, and IL-6 production by acute ethanol treatment. J Leukoc Biol 1995;58:342–350.PubMedGoogle Scholar
  131. 131.
    Saeed RW, Varma S, Peng T, Tracey KJ, Sherry B, Metz CN. Ethanol blocks leukocyte recruitment and endothelial cell activation in vivo and in vitro. J Immunol 2004; 173:6376–6383.PubMedGoogle Scholar
  132. 132.
    Chen GJ, Huang DS, Watzl B, Watson RR. Ethanol modulation of tumor necrosis factor and gamma interferon production by murine splenocytes and macrophages. Life Sci 1993;52:1319–1326.PubMedGoogle Scholar
  133. 133.
    Pruett SB, Zheng Q, Fan R, Matthews K, Schwab C. Ethanol suppresses cytokine responses induced through Toll-like receptors as well as innate resistance to Escherichia coli in a mouse model for binge drinking. Alcohol 2004; 33:147–155.PubMedGoogle Scholar
  134. 134.
    Pruett SB, Schwab C, Zheng Q, Fan R. Suppression of innate immunity by ethanol: a global perspective and a new mechanism beginning with inhibition of signaling through Toll-like receptors 3 and 4. J Immunol 2004; 173: 2715–2724.PubMedGoogle Scholar
  135. 135.
    Mason CM, Dobard E, Kolls JK, Nelson S. Ethanol and murine interleukin (IL)-12 production. Alcohol Clin Exp Res 2000;24:553–559.PubMedGoogle Scholar
  136. 136.
    Saad AJ, Domiati-Saad R, Jerrells TR. Ethanol ingestion increases susceptibility of mice to Listeria monocyto genes. Alcohol Clin Exp Res 1993; 17:75–85.PubMedGoogle Scholar
  137. 137.
    Sibley D, Jerrells TR. Alcohol consumption by C57BL/6 mice is associated with depletion of lymphoid cells from the gut-associated lymphoid tissues and altered resistance to oral infections with Salmonella typhimurium. J Infect Dis 2000;182:482–489.PubMedGoogle Scholar
  138. 138.
    Boe DM, Nelson S, Zhang P, Bagby GJ. Acute ethanol intoxication suppresses lung chemokine production following infection with Streptococcus pneumoniae. J Infect Dis 2001; 184:1134–1142.PubMedGoogle Scholar
  139. 139.
    Greenberg SS, Zhao X, Hua L, Wang JF, Nelson S, Ouyang J. Ethanol inhibits lung clearance of Pseudomonas aeruginosa by a neutrophil and nitric oxidedependent mechanism, in vivo. Alcohol Clin Exp Res 1999;23:735–744.PubMedGoogle Scholar
  140. 140.
    Cotte J, Forestier F, Quero AM, Bourrinet P, German A. The effect of alcohol ingestion on the susceptibility of mice to viral infections. Alcohol Clin Exp Res 1982;6:239–246.PubMedGoogle Scholar
  141. 141.
    Clemens DL, Jerrells TR. Ethanol consumption potentiates viral pancreatitis and may inhibit pancreas regeneration: preliminary findings. Alcohol 2004; 33:183–189.PubMedGoogle Scholar
  142. 142.
    Steven WM, Kumar SN, Stewart GL, Seelig LL Jr. The effects of ethanol consumption on the expression of immunity to Trichinella spiralis in rats. Alcohol Clin Exp Res 1990;14:87–91.PubMedGoogle Scholar
  143. 143.
    Salerno JA, Waltenbaugh C, Cianciotto NP. Ethanol consumption and the susceptibility of mice to Listeria monocytogenes infection. Alcohol Clin Exp Res 2001;25:464–472.PubMedGoogle Scholar
  144. 144.
    Ostrovidov S, Howard LM, Ikeda M, Ikeda A, Waltenbaugh C. Restoration of ethanol-compromised T(h)l responses by sodium orthovanadate. Int Immunol 2002;14:1239–1245.PubMedGoogle Scholar
  145. 145.
    Geissler M, Geisen A, Wands JR. Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids. J Immunol 1997; 159:5107–5113.PubMedGoogle Scholar
  146. 146.
    Han Y-C, Pruett SB. Mechanisms of ethanol-induced suppression of a primary antibody response in a mouse model for binge drinking. J Pharmacol Exp Ther 1995;275:950–957.PubMedGoogle Scholar
  147. 147.
    Encke J, Wands JR. Ethanol inhibition: the humoral and cellular immune response to hepatitis C virus NS5 after genetic Immunization. Alcohol Clin Exp Res 2000;24:1063–1069.PubMedGoogle Scholar
  148. 148.
    Waltenbaugh C, Mikszta J, Ward H, Hsiung L. Alteration of copolymer-specific humoral and cell-mediated immune responses by ethanol. Alcohol Clin Exp Res 1994; 18:1–7.PubMedGoogle Scholar
  149. 149.
    Lieber CS, DeCarli LM. The feeding of ethanol in liquid diets: 1986 update. Alcohol Clin Exp Res 1986; 10:550–553.PubMedGoogle Scholar
  150. 150.
    Padgett EL, Sibley DA, Jerrells TR. Effect of adrenalectomy on ethanol-associated changes in lymphocyte cell numbers and subpopulations in thymus, spleen, and gut-associated lymphoid tissues. Int J Immunopharmacol 2000; 22:285–298.PubMedGoogle Scholar
  151. 151.
    Meadows GG, Blank SE, Duncan DD. Influence of ethanol consumption on natural killer cell activity in mice. Alcohol Clin Exp Res 1989; 13:476–479.PubMedGoogle Scholar
  152. 152.
    Cook RT, Zhu X, Coleman RA, et al. T-cell activation after chronic ethanol ingestion in mice. Alcohol 2004;33:175–181.PubMedGoogle Scholar
  153. 153.
    Gluckman SJ, MacGregor RR. Effect of acute alcohol intoxication on granulocyte mobilization and kinetics. Blood 1978;52:551–559.PubMedGoogle Scholar
  154. 154.
    Szabo G, Chavan S, Mandrekar P, Catalano D. Acute alcohol consumption attenuates interleukin-8 (IL-8) and monocyte chemoattractant peptide-1 (MCP-1) induction in response to ex vivo stimulation. J Clin Immunol 1999; 19:67–76.PubMedGoogle Scholar
  155. 155.
    Girouard L, Mandrekar P, Catalano D, Szabo G. Regulation of monocyte interleukin-12 production by acute alcohol: a role for inhibition by interleukin-10. Alcohol: Clin Exp Res 1998;22:211–216.Google Scholar
  156. 156.
    Mandrekar P, Dolganiuc A, Bellerose G, et al. Acute alcohol inhibits the induction of nuclear regulatory factor kappa B activation through CD 14/ toll-like receptor 4, interleukin-1, and tumor necrosis factor receptors: a common mechanism independent of inhibitory kappa B alpha degradation? Alcohol Clin Exp Res 2002;26:1609–1614.PubMedGoogle Scholar
  157. 157.
    Spies CD, vonDossow V, Eggers V, et al. Altered cell-mediated immunity and increased postoperative infection rate in long-term alcoholic patients. Anesthesiology 2004; 100:1088–1100.PubMedGoogle Scholar
  158. 158.
    Sander M, Irwin M, Sinha P, Naumann E, Kox WJ, Spies CD. Suppression of interleukin-6 to interleukin-10 ratio in chronic alcoholics: association with postoperative infections. Intensive Care Med 2002;28:285–292.PubMedGoogle Scholar
  159. 159.
    Urbaschek R, McCuskey RS, Rudi V, et al. Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. Alcohol Clin Exp Res 2001;25(2):261–268.PubMedGoogle Scholar
  160. 160.
    Yamashina S, Wheeler MD, Rusyn I, Ikejima K, Sato N, Thurman RG. Tolerance and sensitization to endotoxin in Kupffer cells caused by acute ethanol involve interleukin-1 receptor-associated kinase. Biochem Biophys Res Commun 2000;277:686–690.PubMedGoogle Scholar
  161. 161.
    Cook RT, Garvey MJ, Booth BM, Goeken JA, Stewart B, Noel M. Activated CD-8 cells and HLA DR expression in alcoholics without overt liver disease. J Clin Immunol 1991;11:246–253.PubMedGoogle Scholar
  162. 162.
    Song K, Coleman RA, Alber C, et al. TH1 cytokine response of CD57+ T-cell subsets in healthy controls and patients with alcoholic liver disease. Alcohol 2001;24:155–167.PubMedGoogle Scholar
  163. 163.
    Stewart SF, Vidali M, Day CP, Albano E, Jones DE. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. Hepatology 2004;39:197–203.PubMedGoogle Scholar
  164. 164.
    Batey RG, Cao Q, Gould B. Lymphocyte-mediated liver injury in alcoholrelated hepatitis. Alcohol 2002;27:37–41.PubMedGoogle Scholar
  165. 165.
    Jerrells TR. Role of activated CD8+ T cells in the initiation and continuation of hepatic damage. Alcohol 2002;27:47–52.PubMedGoogle Scholar
  166. 166.
    Duryee MJ, Klassen LW, Freeman TL, Willis MS, Tuma DJ, Thiele GM. Lipopolysaccharide is a cofactor for malondialdehyde-acetaldehyde adductmediated cytokine/chemokine release by rat sinusoidal liver endothelial and kupffer cells. Alcohol Clin Exp Res 2004;28:1931–1938.PubMedGoogle Scholar
  167. 167.
    Enomoto N, Ikejima K, Yamashina S, et al. Kupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin. Alcohol Clin Exp Res 2001;25(6 Suppl):51S–S.PubMedGoogle Scholar
  168. 168.
    Fujimoto M, Uemura M, Nakatani Y, et al. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol Clin Exp Res 2000;24(4 Suppl):48S–54S.PubMedGoogle Scholar
  169. 169.
    McClain CJ, Hill DB, Song Z, Deaciuc I, Barve S. Monocyte activation in alcoholic liver disease. Alcohol 2002;27:53–61.PubMedGoogle Scholar
  170. 170.
    Snyder N, Bessoff J, Dwyer JM, Conn HO. Depressed delayed cutaneous hypersensitivity in alcoholic hepatitis. Am J Dig Dis 1978;23:353–358.PubMedGoogle Scholar
  171. 171.
    Thiele GM, Freeman TL, Klassen LW. Immunologic mechanisms of alcoholic liver injury. Semin Liver Dis 2004;24:273–287.PubMedGoogle Scholar
  172. 172.
    Thiagarajan AB, Mefford IN, Eskay RL. Single-dose ethanol administration activates the hypothalamic-pituitary-adrenal axis: exploration of the mechanism of action. Neuroendocrinol 1989;50:427–432.Google Scholar
  173. 173.
    Carson EJ, Pruett SB. Development and characterization of a binge drinking model in mice for evaluation of the immunological effects of ethanol. Alcoholism: Clin Exp Res 1996;20:132–138.Google Scholar
  174. 174.
    Barr CS, Newman TK, Lindell S, et al. Early experience and sex interact to influence limbic-hypothalamic-pituitary-adrenal-axis function after acute alcohol administration in rhesus macaques (Macaca mulatto). Alcohol Clin Exp Res 2004;28:1114–1119.PubMedGoogle Scholar
  175. 175.
    Mendelson JH, Ogata M, Mello NK. Adrenal function and alcoholism. I. Serum cortisol. Psychosom Med 1971;33:145–157.PubMedGoogle Scholar
  176. 176.
    Kutscher S, Heise DJ, Banger M, et al. Concomitant endocrine and immune alterations during alcohol intoxication and acute withdrawal in alcohol-dependent subjects. Neuropsychobiology 2002;45(3): 144–149.PubMedGoogle Scholar
  177. 177.
    Pruett SB, Collier SD, Wu W-J. Ethanol-induced activation of the hypothalamic-pituitary-adrenal axis in a mouse model for binge drinking: role of Rol5-4513-sensitive gamma aminobutyric acid receptors, tolerance, and relevance to humans. Life Sci 1998;63:1137–1146.PubMedGoogle Scholar
  178. 178.
    Barber AE, Coyle SM, Marano MA, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993; 150: 1999–2006.PubMedGoogle Scholar
  179. 179.
    Ruzek MC, Pearce BD, Miller AH, Biron CA. Endogenous glucocorticoids protect against cytokine-mediated lethality during viral infection. J Immunol 1999;162:3527–3533.PubMedGoogle Scholar
  180. 180.
    Zhang D, Kishihara K, Wang B, Mizobe K, Kubo C, Nomoto K. Restraint stress-induced immunosuppression by inhibiting leukocyte migration and Th1 cytokine expression during the intraperitoneal infection of Listeria monocytogenes. J Neuroimmunol 1998;92:139–151.PubMedGoogle Scholar
  181. 181.
    Swain MG, Appleyard C, Wallace J, Wong H, Le T. Endogenous glucocorticoids released during acute toxic liver injury enhance hepatic IL-10 synthesis and release. Am J Physiol 1999;276:G199–G205.PubMedGoogle Scholar
  182. 182.
    Vinson RB, Carroll JL, Pruett SB. Mechanism of supressed neutrophil mobilization in a mouse model for binge drinking: role of glucocorticoids. Am Physiol Soc 1998;275:R1049–R1057.Google Scholar
  183. 183.
    Eskay RL, Chautard T, Torda T, Hwang D. The effects of alcohol on selected regulatory aspects of the stress axis. NIAAA Res Mono 1993;23:3–19.Google Scholar
  184. 184.
    Merry J, Marks V. Plasma-hydrocortisone response to ethanol in chronic alcoholics. Lancet 1969;l:921–923.Google Scholar
  185. 185.
    Epstein EE, Kahler CW, McCrady BS, Lewis KD, Lewis S. An empirical classification of drinking patterns among alcoholics: binge, episodic, sporadic, and steady. Addict Behav 1995;20:23–41.PubMedGoogle Scholar
  186. 186.
    Nakamura Y, Yokoyama H, Higuchi S, Hara S, Kato S, Ishii H. Acetaldehyde accumulation suppresses Kupffer cell release of TNF-Alpha and modifies acute hepatic inflammation in rats. J Gastroenterol 2004;39:140–147.PubMedGoogle Scholar
  187. 187.
    Pauly T, Dahmen N, Szegedi A, et al. Blood ethanol levels and adenylyl cyclase activity in lymphocytes of alcoholic patients. Biol Psychiatry 1999; 45:489–493.PubMedGoogle Scholar
  188. 188.
    Pruett SB, Fan R, Zheng Q. Acute ethanol administration profoundly alters poly I:C-induced cytokine expression in mice by a mechanism that is not dependent on corticosterone. Life Sci 2003;72:1825–1839.PubMedGoogle Scholar
  189. 189.
    Goral J, Choudhry MA, Kovacs EJ. Acute ethanol exposure inhibits macrophage IL-6 production: role of p38 and ERK1/2 MAPK. J Leukoc Biol 2004;75:553–559.PubMedGoogle Scholar
  190. 190.
    Hoffmann D, Wynder EL. Chemical constituents and bioactivity of tobacco smoke. IARC Sci Publ 1986:145–165.Google Scholar
  191. 191.
    Anthony DC, Montine TJ, Valentine WM, Graham DG. Toxic responses of the nervous system. In: Klaassen CD, ed. Casarett and Doull’s Toxicology. New York: McGraw-Hill; 2001, pp. 555–557.Google Scholar
  192. 192.
    Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002;2:372–377.PubMedGoogle Scholar
  193. 193.
    Gilbert DG, Meliska CJ, Williams CL, Jensen RA. Subjective correlates of cigarette-smoking-induced elevations of peripheral beta-endorphin and cortisol. Psychopharmacol 1992; 106:275–281.Google Scholar
  194. 194.
    Pomerleau OF, Pomerleau CS. Cortisol response to a psychological Stressor and/or nicotine. Pharmacol Biochem Behav 1990;36:211–213.PubMedGoogle Scholar
  195. 195.
    Russell MA, Jarvis M, Iyer R, Feyerabend C. Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers. Br Med J 1980;280: 972–976.PubMedGoogle Scholar
  196. 196.
    Cullen JW, ed. The Health Consequences of Using Smokless Tobacco. Bethesda, Maryland: U.S. Department of Health and Human Services; 1986.Google Scholar
  197. 197.
    Russell MA, Jarvis MJ, Devitt G, Feyerabend C. Nicotine intake by snuff users. Br Med J (Clin Res Ed) 1981;283:814–817.Google Scholar
  198. 198.
    Nouri-Shirazi M, Guinet E. Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. Immunology 2003;109:365–373.PubMedGoogle Scholar
  199. 199.
    Pruett SB, Han Y, Munson AE, Fuchs BA. Assessment of cholinergic influences on a primary humoral immune response. Immunol 1992;77:428–435.Google Scholar
  200. 200.
    Wang H, Liao H, Ochani M, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004;10:1216–1221.PubMedGoogle Scholar
  201. 201.
    Matsunaga K, Klein TW, Friedman H, Yamamoto Y. Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J Immunol 2001;167:6518–6524.PubMedGoogle Scholar
  202. 202.
    Geng Y, Savage SM, Johnson LJ, Seagrave J, Sopori ML. Effects of nicotine on the immune response. I. Chronic exposure to nicotine impairs antigen receptor-mediated signal transduction in lymphocytes. Toxicol Appl Pharmacol 1995; 135:268–278.PubMedGoogle Scholar
  203. 203.
    Aicher A, Heeschen C, Mohaupt M, Cooke JP, Zeiher AM, Dimmeier S. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation 2003; 107:604–611.PubMedGoogle Scholar
  204. 204.
    Thomas GA, Rhodes J, Green JT. Inflammatory bowel disease and smoking-a review. Am J Gastroenterol 1998;93:144–149.PubMedGoogle Scholar
  205. 205.
    Arnott ID, Williams N, Drummond HE, Ghosh S. Whole gut lavage fluid interleukinlbeta and interleukin-8 in smokers and non-smokers with Crohn’s disease in clinical remission. Dig Liver Dis 2002;34:424–429.PubMedGoogle Scholar
  206. 206.
    Sher ME, Bank S, Greenberg R, et al. The influence of cigarette smoking on cytokine levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 1999;5:73–78.PubMedGoogle Scholar
  207. 207.
    Yang H, Wang H, Tracey KJ. HMG-1 rediscovered as a cytokine. Shock 2001; 15:247–253.PubMedGoogle Scholar
  208. 208.
    Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001; 164:1768–1773.PubMedGoogle Scholar
  209. 209.
    Mellon RD, Bayer BM. The effects of morphine, nicotine and epibatidine on lymphocyte activity and hypothalmic-pituitary-adrenal axis responses. J Pharm Exp Ther 1999;288:635–642.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Authors and Affiliations

  • Stephen B. Pruett
    • 1
  1. 1.Department of Cellular Biology and AnatomyLSUHSCShreveport

Personalised recommendations